Adagrasib (MRTX849) is a potent, orally available, and mutation-selective covalent KRAS G12C inhibitor. It binds irreversibly to cysteine 12, locking KRAS in its inactive GDP-bound state and blocking KRAS-dependent signaling for potential antitumor activity. Reagent-grade; for laboratory research purposes only.
Usually ships within 24 hours.